Fundraising Fox
/Companies
Sign in

Rhythm Pharmaceuticals

Boston, US · Founded 2013 · 494 employees on LinkedIn · 7 known investors

Find your way into Rhythm Pharmaceuticals

Sign up to see every warm intro you have to Rhythm Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Rhythm Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

KGKeith Gottesdiener
Keith GottesdienerPresident and Chief Executive Officer2011–2020Investor at Prime Medicine, Inc.
BHBart Henderson
Bart HendersonPresident and Founder2008–2017Bart Henderson founded Rhythm Pharmaceuticals and co-founded Torque (later Repertoire); he was a founding employee at Radius, where he contributed to the development of multiple FDA-approved medicines including treatments for osteoporosis and metastatic breast cancer.
DMDavid Meeker
David MeekerPresident and Chief Executive OfficerPRESIDENT AND CHIEF EXECUTIVE OFFICER at KSQ Therapeutics

Board

ETEdward T. Mathers
Edward T. MathersBoard directorPartner at New Enterprise Associates (NEA)
JSJonathan Silverstein
Jonathan SilversteinBoard directorPartner at OrbiMed
NENeil Exter
Neil ExterBoard directorRetired Partner at Third Rock Ventures
TF
Todd FoleyBoard director
CJ
Christophe JeanBoard director
DJ
David J. McGirrBoard director
DP
David P. Meeker, M.D.Board director

Investors · 7

HEALTHCARE ROYALTY PARTNERSlisted by HEALTHCARE ROYALTY PARTNERSNew York
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M
OrbiMedinferredNew York · $1M – $75Mvia Jonathan Silverstein · board

How we know: board seat on SEC Form D · Not right? Tell us

Third Rock VenturesinferredBoston · $100K – $5Mvia Neil Exter · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$60.5M disclosed across 2 rounds · 2015–2017

▶$20.5MraisedJan 2017 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David P. Meeker, M.D.Director
  • Neil ExterDirector
  • David J. McGirrDirector
  • Jonathan SilversteinDirector
  • Edward T. MathersDirector
  • Christophe JeanDirector
  • Bart HendersonExecutive Officer, Promoter
  • Todd FoleyDirector
  • Keith GottesdienerExecutive Officer, Director, Promoter
Offering amount
$40.9M
Amount sold
$20.5M
First sale
Jan 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40MraisedDec 2015 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward T. MathersDirector
  • David J. McGirrDirector
  • Jonathan SilversteinDirector
  • Keith GottesdienerExecutive Officer, Director
  • David P. Meeker, M.D.Director
  • Neil ExterDirector
  • Bart HendersonExecutive Officer
  • Todd FoleyDirector
  • Christophe JeanDirector
Offering amount
$40M
Amount sold
$40M
First sale
Aug 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through Rhythm Pharmaceuticals went on to found or lead other companies.

Andrew GottesdienerSummer InternFounded Apogee Therapeutics +1Elizabeth StonerSenior Clinical AdvisorFounded Semma TherapeuticsBart HendersonMr. Henderson is the President and Treasurer of the Issuer.Founded WavebreaktxJennifer GoodBoard MemberFounded Trevi Therapeutics

In the news

Rhythm Pharmaceuticals, Inc. - MassBiomassbio.org · Aug 2026

Frequently asked questions

What does Rhythm Pharmaceuticals do?
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.
Who are Rhythm Pharmaceuticals's investors?
Rhythm Pharmaceuticals's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA), Pfizer Venture Investments, Wellington Management, OrbiMed, Third Rock Ventures.
How much funding has Rhythm Pharmaceuticals raised?
Rhythm Pharmaceuticals has disclosed $60.5M raised across 2 rounds.
Where is Rhythm Pharmaceuticals headquartered?
Rhythm Pharmaceuticals is headquartered in Boston, US.